BeiGene
BeiGene is a global biotechnology company, expediting development of a diverse pipeline of novel therapeutics to improve treatment outcomes and access for patients worldwide. Our growing global team spans five continents, with administrative offices in Beijing, China; Cambridge, U.S.; and Basel, Switzerland. Our internally discovered medicine BRUKINSA® (zanubrutinib) is approved in more than 60 markets, including the United States, China, the European Union, Canada, Australia, South Korea. For more information visit Brukinsa.com/hcp